Skip to Content
Merck
CN
All Photos(1)

Documents

P2950000

Primidone

European Pharmacopoeia (EP) Reference Standard

Sign Into View Organizational & Contract Pricing
All Photos(1)
Synonym(s):
2-Desoxyphenobarbital, 5-Ethyl-5-phenylhexahydropyrimidine-4,6-dione
Empirical Formula (Hill Notation):
C12H14N2O2
CAS Number:
125-33-7
Molecular Weight:
218.25
MDL number:
MFCD00038662
UNSPSC Code:
41116107
PubChem Substance ID:
329820157
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

primidone

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CCC1(C(=O)NCNC1=O)c2ccccc2

InChI

1S/C12H14N2O2/c1-2-12(9-6-4-3-5-7-9)10(15)13-8-14-11(12)16/h3-7H,2,8H2,1H3,(H,13,15)(H,14,16)

InChI key

DQMZLTXERSFNPB-UHFFFAOYSA-N

Gene Information

human ... GABRA1(2554) , GABRA2(2555) , GABRA3(2556) , GABRA4(2557) , GABRA5(2558) , GABRA6(2559) , GABRB1(2560) , GABRB2(2561) , GABRB3(2562) , GABRD(2563) , GABRE(2564) , GABRG1(2565) , GABRG2(2566) , GABRG3(2567) , GABRP(2568) , GABRQ(55879) , SCN10A(6336) , SCN11A(11280) , SCN1A(6323) , SCN2A(6326) , SCN3A(6328) , SCN4A(6329) , SCN5A(6331) , SCN7A(6332) , SCN8A(6334) , SCN9A(6335)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Primidone EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

1562000

Primidone, United States Pharmacopeia (USP) Reference Standard

1562033

Primidone Related Compound C, United States Pharmacopeia (USP) Reference Standard

1562011

Primidone Related Compound A, United States Pharmacopeia (USP) Reference Standard

BP293

Primidone, British Pharmacopoeia (BP) Reference Standard

Y0002215

Primidone for system suitability, CRS European Pharmacopoeia (EP) Reference Standard

PHR3109

Primidone, pharmaceutical secondary standard, certified reference material

PHR3110

Primidone Related Compound A, pharmaceutical secondary standard, certified reference material

PHR3111

Primidone Related Compound C, pharmaceutical secondary standard, certified reference material

Pictograms

Health hazardExclamation mark
GHS08,GHS07

Signal Word

Warning

Hazard Statements

H302,H351,H361d

Hazard Classifications

Acute Tox. 4 Oral - Carc. 2 - Repr. 2

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

[Primidone].
K Furuno et al.
Nihon rinsho. Japanese journal of clinical medicine, 53 Su Pt 1, 928-930 (1995-02-01)
R Wilbur et al.
American journal of hospital pharmacy, 38(8), 1138-1143 (1981-08-01)
The evidence for the efficacy of anticonvulsant drugs in the control of seizures during alcohol withdrawal is examined. The literature on the use of anticonvulsants to control anxiety, irritability, tension, and other symptoms of abstinence syndrome is reviewed. The data
Sofia Markoula et al.
Therapeutic drug monitoring, 36(4), 494-498 (2014-02-25)
Lacosamide (LCM), a new antiepileptic drug (AED) approved as adjunctive therapy for the treatment of patients with partial-onset seizures, has limited pharmacokinetic and drug interaction data. The main objectives of the present study were to investigate the effects of dose
Reo Tanoshima et al.
Therapeutic drug monitoring, 35(2), 145-149 (2013-03-19)
A 7.5-year-old girl who was treated with phenobarbital (PHB) for epilepsy was admitted with decreased levels of consciousness. She had been known to have high PHB levels of unknown cause, without symptoms. Her PHB levels were very high, as expected
D Christidis et al.
Seizure, 15(1), 64-66 (2005-11-29)
Sudden unexplained/unexpected death (SUDEP) in epilepsy is a major cause of death accounting for 7-17% of the mortality among epileptic patients. Prolongation of QT-interval has been issued as a major mechanism in SUDEP since it is associated with fatal cardiac
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service